Factbox-Top pharma companies racing to launch a weight-loss pill [Yahoo! Finance]
Eli Lilly and Company (LLY)
Last eli lilly and company earnings: 4/23 06:25 am
Check Earnings Report
US:NYSE Investor Relations:
investor.lilly.com
Company Research
Source: Yahoo! Finance
The fast-changing landscape has ?prompted Wall Street to rethink long-held forecasts of a $150 billion market within the next decade. Novo became the first company to ?launch a GLP-1 pill for obesity, giving the Danish drugmaker a competitive edge in the fast-evolving obesity treatment market. Here are some companies racing to develop oral obesity drugs ?in the hopes of making their mark in a lucrative market: ELI LILLY Orforglipron, the company's once-daily oral non-peptide GLP-1 agonist, helped overweight adults without diabetes lose 12.4% of their body weight over 72 weeks at the highest dose in a late-stage trial. In another study, orforglipron helped maintain weight loss in patients switching from its GLP-1 injection, Zepbound, and rival Novo Nordisk's Wegovy. The company is preparing to launch orforglipron in the U.S. as early as ?the second quarter of this year, pending approval from ?the Food and Drug Administration. STRUCTURE THERAPEUTICS Structure Therapeuti
Show less
Read more
Impact Snapshot
Event Time:
LLY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LLY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LLY alerts
High impacting Eli Lilly and Company news events
Weekly update
A roundup of the hottest topics
LLY
News
- Lilly (LLY) Down 3.7% Since Last Earnings Report: Can It Rebound? [Yahoo! Finance]Yahoo! Finance
- Eli Lilly and Company (LLY) had its "buy" rating reaffirmed by Deutsche Bank Aktiengesellschaft.MarketBeat
- GLP-1 drugs linked to lower addiction risk, study finds [USA TODAY]USA TODAY
- GLP-1 Receptor Agonist (Trulicity, Wegovy, Ozempic, Mounjaro) Market Trends Analysis Report 2026 [Yahoo! Finance]Yahoo! Finance
- Lilly Stock Down 5% in a Month: Should You Buy Now or Steer Clear? [Yahoo! Finance]Yahoo! Finance
LLY
Earnings
- 2/4/26 - Beat
LLY
Sec Filings
- 3/6/26 - Form PRE
- 2/19/26 - Form 4
- 2/18/26 - Form 4
- LLY's page on the SEC website